PeerVoice Brain & Behaviour Audio PeerVoice

Visit https://www.peervoice.com/JEG860 to view the entire programme with slides. After completing “Ali Aamer Habib, MD - Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis”, participants will be able to: Describe the limitations of current targeted immunotherapies for patients with generalised myasthenia gravis (gMG); Identify emerging targeted therapies for gMG; and Explain how emerging targeted therapies for gMG differentiate from other therapies within the same class.

Visit https://www.peervoice.com/PBV860 to view the entire programme with slides. After completing “Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis”, participants will be able to: Describe the role of autoantibodies in the pathophysiology of generalised myasthenia gravis (gMG); Identify the specific autoantibodies associated with gMG and the effects they have on the neuromuscular junction (NMJ); Explain why identifying autoantibody specificity is important for optimising clinical outcomes in patients with gMG; and Use the serological autoantibody status of patients with gMG to determine which therapeutic class is most appropriate for optimising clinical outcomes.

Visit https://www.peervoice.com/HPE860 to view the entire programme with slides. After completing “Carel le Roux, MD, PhD - Prioritising Obesity Care in Our Clinical Practices: Why We Must and How We Can”, participants will be able to: Apply best practices for the screening and formal diagnosis of obesity as a chronic disease; Identify patients who would benefit from treatment or referral for management of obesity; and Evaluate current and emerging strategies for treating obesity as a chronic disease.

Visit https://www.peervoice.com/SNX860 to view the entire programme with slides. After completing “Laurent Servais, MD, PhD - Catch Them Before They Fall: A Call to Action for Comprehensive Testing for Hypotonia in Paediatric Patients”, participants will be able to: Describe the clinical presentation and differential diagnosis of hypotonia in paediatric patients; Explain the rationale for comprehensive genetic testing for specific causes of hypotonia, including spinal muscular atrophy (SMA); and Formulate best practices for referral and linkage to care for testing and management of hypotonia due to treatable genetic disorders, such as SMA.

Visit https://www.peervoice.com/SCT860 to view the entire programme with slides. After completing “Andreea Ciudin, MD, PhD - Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on the Modernisation of Obesity Care”, participants will be able to: Explain the rationale for screening for and formally diagnosing obesity as a chronic disease; Apply best practices for communication with people who have obesity about the associated risks and treatment options; and Apply a multidisciplinary, multispeciality approach to obesity care.

Visit https://www.peervoice.com/THW860 to view the entire programme with slides. After completing “Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers”, participants will be able to: Identify unmet needs in the identification and diagnosis of patients with transthyretin amyloidosis (ATTR); and Apply recommended approaches to promote accurate and timely diagnosis and intervention in ATTR.